Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
5 March 2025 at 8.30 EET

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 3 March 2025 below five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

	% of shares and voting rights (total of point A)	% of shares and voting rights through financial instruments (total of point B)	Total of both in % (points A + B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	Below 5% shares Below 5% voting rights	Below 5% shares Below 5% voting rights	Below 5% shares Below 5% voting rights	141,134,278 shares 763,427,275 voting rights
Position of previous notification (if applicable)	4.98% shares Below 5% voting rights	0.01% shares Below 5% voting rights	5.00% shares Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI0009014377		Below 5% shares Below 5% voting rights		Below 5% shares Below 5% voting rights
POINT A SUBTOTAL	Below 5% shares Below 5% voting rights		Below 5% shares Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument	Expiration date	Exercise / Conversion Period	Physical or cash settlement	Number of shares and voting rights	% of shares and voting rights
Securities Lent	N/A	N/A	Physical	Below 5% shares Below 5% voting rights	Below 5% shares Below 5% voting rights
			POINT B SUBTOTAL	Below 5% shares Below 5% voting rights	Below 5% shares Below 5% voting rights

Orion Corporation

Liisa Hurme

President and CEO

Olli Huotari

EVP, Corporate Functions

Contact person:
Terhi Ormio, VP, Communications
Orion Corporation
Tel. +358 50 966 4646

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.